Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
5.7
3.0
Journals
JCM
Special Issues
Lymphoma：New Diagnosis and Current Treatment Strategies
jcm-logo
Submit to JCM Review for JCM Propose a Special Issue

Journal Menu

► Journal Menu

Journal Browser

► Journal Browser
share announcement

Lymphoma：New Diagnosis and Current Treatment Strategies

A special issue of Journal of Clinical Medicine (ISSN 2077-0383). This special issue belongs to the section "Hematology".

Deadline for manuscript submissions: closed (30 November 2021) | Viewed by 27177

Special Issue Editor

Prof. Dr. Kai Huebel

E-Mail Website
Guest Editor
University Hospital Cologne (AöR), Kerpener Str. 62, 50937 Cologne, Germany
Interests: indolent lymphoma; aggressive lymphoma; Hodgkin’s lymphoma; Non-Hodgkin lymphomas; stem cell transplantation; mobilization

Special Issue Information

Dear Colleagues,

Lymphomas represent an important topic in the spectrum of hematologic diseases, and the majority of physicians will probably have come across a patient with lymphoma. Traditionally, lymphomas are divided into Hodgkin’s lymphoma and non-Hodgkin’s lymphoma, with B cell non-Hodgkin’s lymphoma as the most frequent one. More important, clinical presentation varies widely between patients, from most indolent to most aggressive malignancies. However, in several lymphoma subtypes, the overall prognosis has substantially improved over the last few decades, based on new diagnostic tools and the broadening of the therapeutic armamentarium. The efficacy of classic chemotherapy or immunochemotherapy has been augmented by new compounds selectively targeting the cell surface, intracellular pathways or the microenvironment. Some of them have already been approved or are close to getting licensed. In the relapsed situation, autologous or allogeneic hematopoietic stem cell transplantation may be an option. The therapeutic landscape was further changed by the introduction of “CAR T cell therapy”, an innovative approach for high-risk lymphoma patients.

In summary, the management of patients with lymphomas is still challenging but exciting. In this Special Issue, we will discuss major aspects of lymphoma diagnosis and therapy, from treatment-naïve patients to relapsed and refractory patients, including special situations and prognosis.

Prof. Dr. Kai Huebel
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Clinical Medicine is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • Indolent lymphoma
  • Aggressive lymphoma
  • Hodgkin’s lymphoma
  • Diagnosis
  • Immunotherapy
  • Targeted drugs
  • Stem cell transplantation
  • CAR T cells
  • Relapse
  • Prognosis

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (6 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Editorial

Jump to: Research, Review, Other

3 pages, 170 KiB  
Editorial
Lymphoma: New Diagnosis and Current Treatment Strategies
by Kai Hübel
J. Clin. Med. 2022, 11(6), 1701; https://doi.org/10.3390/jcm11061701 - 19 Mar 2022
Cited by 1 | Viewed by 1958
Abstract
Historically, the treatment of patients with lymphoma has been based on three columns, with ascending importance: surgery, radiation, and chemotherapy [...] Full article
(This article belongs to the Special Issue Lymphoma：New Diagnosis and Current Treatment Strategies)

Research

Jump to: Editorial, Review, Other

13 pages, 435 KiB  
Article
Total Lesion Glycolysis Improves Tumor Burden Evaluation and Risk Assessment at Diagnosis in Hodgkin Lymphoma
by Ines Herraez, Leyre Bento, Jaume Daumal, Alessandra Repetto, Raquel Del Campo, Sandra Perez, Rafael Ramos, Javier Ibarra, Francesc Mestre, Joan Bargay, Paloma Lopez, Joan Garcias-Ladaria, Antonia Sampol and Antonio Gutierrez
J. Clin. Med. 2021, 10(19), 4396; https://doi.org/10.3390/jcm10194396 - 26 Sep 2021
Cited by 15 | Viewed by 2636
Abstract
Hodgkin lymphoma (HL) is a hematological malignancy with an excellent prognosis. However, we still need to identify those patients that could experience failed standard frontline chemotherapy. Tumor burden evaluation and standard decisions are based on Ann Arbor (AA) staging, but this approach may [...] Read more.
Hodgkin lymphoma (HL) is a hematological malignancy with an excellent prognosis. However, we still need to identify those patients that could experience failed standard frontline chemotherapy. Tumor burden evaluation and standard decisions are based on Ann Arbor (AA) staging, but this approach may be insufficient in predicting outcomes. We aim to study new ways to assess tumor burden through volume-based PET parameters to improve the risk assessment of HL patients. We retrospectively analyzed 101 patients with HL from two hospitals in the Balearic Islands between 2011 and 2018. Higher metabolic tumor volume (MTV) and total lesion glycolysis (TLG) were significantly associated with a higher incidence of III-IV AA stages, B-symptoms, hypoalbuminemia, lymphopenia, and higher IPS. Standardized uptake value (SUVmax) was significantly related to AA stage and hypoalbuminemia. We found that TLG or the combination of SUVmax, TLG, and MTV significantly improved the risk assessment when compared to AA staging. We conclude that TLG is the best single PET/CT-related tumor-load parameter that significantly improves HL risk assessment when compared to AA staging. If confirmed in a larger and validated sample, this information could be used to modify standard frontline therapy and justifies the inclusion of TLG inside an HL prognostic score. Full article
(This article belongs to the Special Issue Lymphoma：New Diagnosis and Current Treatment Strategies)
►▼ Show Figures

Figure 1

12 pages, 260 KiB  
Article
Computed Tomography Structured Reporting in the Staging of Lymphoma: A Delphi Consensus Proposal
by Vincenza Granata, Silvia Pradella, Diletta Cozzi, Roberta Fusco, Lorenzo Faggioni, Francesca Coppola, Roberta Grassi, Nicola Maggialetti, Duccio Buccicardi, Giorgia Viola Lacasella, Marco Montella, Eleonora Ciaghi, Francesco Bellifemine, Massimo De Filippo, Marco Rengo, Chandra Bortolotto, Roberto Prost, Carmelo Barresi, Salvatore Cappabianca, Luca Brunese, Emanuele Neri, Roberto Grassi and Vittorio Mieleadd Show full author list remove Hide full author list
J. Clin. Med. 2021, 10(17), 4007; https://doi.org/10.3390/jcm10174007 - 4 Sep 2021
Cited by 18 | Viewed by 3489
Abstract
Structured reporting (SR) in radiology is becoming increasingly necessary and has been recognized recently by major scientific societies. This study aims to build structured CT-based reports for lymphoma patients during the staging phase to improve communication between radiologists, members of multidisciplinary teams, and [...] Read more.
Structured reporting (SR) in radiology is becoming increasingly necessary and has been recognized recently by major scientific societies. This study aims to build structured CT-based reports for lymphoma patients during the staging phase to improve communication between radiologists, members of multidisciplinary teams, and patients. A panel of expert radiologists, members of the Italian Society of Medical and Interventional Radiology (SIRM), was established. A modified Delphi process was used to develop the SR and to assess a level of agreement for all report sections. The Cronbach’s alpha (Cα) correlation coefficient was used to assess internal consistency for each section and to measure quality analysis according to the average inter-item correlation. The final SR version was divided into four sections: (a) Patient Clinical Data, (b) Clinical Evaluation, (c) Imaging Protocol, and (d) Report, including n = 13 items in the “Patient Clinical Data” section, n = 8 items in the “Clinical Evaluation” section, n = 9 items in the “Imaging Protocol” section, and n = 32 items in the “Report” section. Overall, 62 items were included in the final version of the SR. A dedicated section of significant images was added as part of the report. In the first Delphi round, all sections received more than a good rating (≥3). The overall mean score of the experts and the sum of score for structured report were 4.4 (range 1–5) and 1524 (mean value of 101.6 and standard deviation of 11.8). The Cα correlation coefficient was 0.89 in the first round. In the second Delphi round, all sections received more than an excellent rating (≥4). The overall mean score of the experts and the sum of scores for structured report were 4.9 (range 3–5) and 1694 (mean value of 112.9 and standard deviation of 4.0). The Cα correlation coefficient was 0.87 in this round. The highest overall means value, highest sum of scores of the panelists, and smallest standard deviation values of the evaluations in this round reflect the increase of the internal consistency and agreement among experts in the second round compared to first round. The accurate statement of imaging data given to referring physicians is critical for patient care; the information contained affects both the decision-making process and the subsequent treatment. The radiology report is the most important source of clinical imaging information. It conveys critical information about the patient’s health and the radiologist’s interpretation of medical findings. It also communicates information to the referring physicians and records this information for future clinical and research use. The present SR was generated based on a multi-round consensus-building Delphi exercise and uses standardized terminology and structures, in order to adhere to diagnostic/therapeutic recommendations and facilitate enrolment in clinical trials, to reduce any ambiguity that may arise from non-conventional language, and to enable better communication between radiologists and clinicians. Full article
(This article belongs to the Special Issue Lymphoma：New Diagnosis and Current Treatment Strategies)

Review

Jump to: Editorial, Research, Other

17 pages, 754 KiB  
Review
Hodgkin Lymphoma—Review on Pathogenesis, Diagnosis, Current and Future Treatment Approaches for Adult Patients
by Jesko Momotow, Sven Borchmann, Dennis A. Eichenauer, Andreas Engert and Stephanie Sasse
J. Clin. Med. 2021, 10(5), 1125; https://doi.org/10.3390/jcm10051125 - 8 Mar 2021
Cited by 37 | Viewed by 11527
Abstract
Hodgkin lymphoma (HL) is a rare malignancy accounting for roughly 15% of all lymphomas and mostly affecting young patients. A second peak is seen in patients above 60 years of age. The history of HL treatment represents a remarkable success story in which [...] Read more.
Hodgkin lymphoma (HL) is a rare malignancy accounting for roughly 15% of all lymphomas and mostly affecting young patients. A second peak is seen in patients above 60 years of age. The history of HL treatment represents a remarkable success story in which HL has turned from an incurable disease to a neoplasm with an excellent prognosis. First-line treatment with stage-adapted treatment consisting of chemotherapy and/or radiotherapy results in cure rates of approximately 80%. Second-line treatment mostly consists of intensive salvage chemotherapy followed by high-dose chemotherapy (HDCT) and autologous stem cell transplantation (ASCT). Novel approaches such as antibody drug conjugates and immunomodulatory drugs have shown impressive results in clinical trials in refractory and relapsed HL and are now increasingly implemented in earlier treatment lines. This review gives a comprehensive overview on HL addressing epidemiology, pathophysiology and current treatment options as well as recent developments and perspectives. Full article
(This article belongs to the Special Issue Lymphoma：New Diagnosis and Current Treatment Strategies)
►▼ Show Figures

Figure 1

9 pages, 477 KiB  
Review
The Role of Autoimmune Diseases in the Prognosis of Lymphoma
by Pierluigi Masciopinto, Grazia Dell’Olio, Rosa De Robertis, Giorgina Specchia, Pellegrino Musto and Francesco Albano
J. Clin. Med. 2020, 9(11), 3403; https://doi.org/10.3390/jcm9113403 - 23 Oct 2020
Cited by 11 | Viewed by 2879
Abstract
The connection between autoimmune disease (AID) and lymphoproliferative disorders is a complex bidirectional relationship that has long been a focus of attention by researchers and physicians. Although advances in pathobiology knowledge have ascertained an AID role in the development of lymphoproliferative diseases developing, [...] Read more.
The connection between autoimmune disease (AID) and lymphoproliferative disorders is a complex bidirectional relationship that has long been a focus of attention by researchers and physicians. Although advances in pathobiology knowledge have ascertained an AID role in the development of lymphoproliferative diseases developing, results about AID influence on the prognosis of lymphoma are discordant. In this review, we collect the most relevant literature debating a direct or indirect link between immune-mediated diseases and lymphoma prognosis. We also consider the molecular, genetic, and microenvironmental factors involved in the pathobiology of these diseases in order to gain a deeper understanding of the nature of this link. Full article
(This article belongs to the Special Issue Lymphoma：New Diagnosis and Current Treatment Strategies)
►▼ Show Figures

Figure 1

Other

17 pages, 1583 KiB  
Brief Report
Chemokine Receptors CCR1 and CCR2 on Peripheral Blood Mononuclear Cells of Newly Diagnosed Patients with the CD38-Positive Chronic Lymphocytic Leukemia
by Irina Kholodnyuk, Alla Rivkina, Laura Hippe, Simons Svirskis, Svetlana Kozireva, Ildze Ventina, Irina Spaka, Marina Soloveichika, Jelena Pavlova, Modra Murovska and Sandra Lejniece
J. Clin. Med. 2020, 9(7), 2312; https://doi.org/10.3390/jcm9072312 - 21 Jul 2020
Cited by 2 | Viewed by 2941
Abstract
Chemokines and their receptors direct migration and infiltration of immune cells. CCR1 and CCR2 maintain sequence similarity and respond to a number of the same chemokines secreted in lymphoid organs. Expression of CD38 on leukemic cells has been associated with poor clinical outcomes [...] Read more.
Chemokines and their receptors direct migration and infiltration of immune cells. CCR1 and CCR2 maintain sequence similarity and respond to a number of the same chemokines secreted in lymphoid organs. Expression of CD38 on leukemic cells has been associated with poor clinical outcomes in patients with chronic lymphocytic leukemia (CLL) and is considered as the negative predictor of progression. In our study of newly diagnosed CLL patients, which included 39 CD38-positive and 22 CD38-negative patients, CCR1 and/or CCR2 were always detected, using flow cytometry, on the peripheral blood (PB) CD19+CD5+ lymphocytes in patients with >30% of the CD38+ CD19+CD5+ lymphocytes (n = 16). Spearman’s rank correlation analysis determined correlations between the frequency of the CCR1- and CCR2-expressing PB CD19+CD5+ lymphocytes and the frequency of the CD38-positive CD19+CD5+ lymphocytes (rs = 0.50 and rs = 0.38, respectively). No significant correlations were observed between ZAP70 mRNA expression levels in PB mononuclear cells and the frequency of the circulating CCR1+ or CCR2+ CD19+CD5+ lymphocytes. Further association studies are needed to verify prognostic relevance of the CCR1/CCR2 expression on leukemic cells in CLL patients at diagnosis. We suggest that CCR1/CCR2 signaling pathways could represent attractive targets for development of CLL anti-progression therapeutics. Full article
(This article belongs to the Special Issue Lymphoma：New Diagnosis and Current Treatment Strategies)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-6
Back to TopTop